A Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)

NCT ID: NCT03978520

Last Updated: 2023-07-21

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

341 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-07-25

Study Completion Date

2022-07-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main objective of this study was to evaluate the safety and efficacy of elsubrutinib, upadacitinib (UPA), and ABBV-599 (elsubrutinib/upadacitinib) High Dose and Low Dose combinations vs placebo for the treatment of signs and symptoms of Systemic Lupus Erythematosus (SLE) in participants with moderately to severely active SLE and to define doses for further development.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Systemic Lupus Erythematosus (SLE)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Elsubrutinib placebo/upadacitinib placebo

Placebo capsule for elsubrutinib once a day by mouth for up to 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for up to 48 weeks

Group Type PLACEBO_COMPARATOR

Placebo for elsubrutinib

Intervention Type DRUG

Capsule; Oral

Placebo for upadacitinib

Intervention Type DRUG

Film-coated tablet; Oral

ABBV-599 High Dose (Elsubrutinib 60 mg/upadacitinib 30 mg)

60 mg elsubrutinib capsule once a day by mouth for up to 48 weeks; 30 mg upadacitinib film-coated tablet once a day by mouth for up to 48 weeks

Group Type EXPERIMENTAL

Elsubrutinib

Intervention Type DRUG

Capsule; Oral

Upadacitinib

Intervention Type DRUG

Film-coated tablet; Oral

Elsubrutinib placebo/upadacitinib 30 mg

Placebo capsule for elsubrutinib once a day by mouth for up to 48 weeks; 30 mg upadacitinib film-coated tablet once a day by mouth for up to 48 weeks

Group Type EXPERIMENTAL

Placebo for elsubrutinib

Intervention Type DRUG

Capsule; Oral

Upadacitinib

Intervention Type DRUG

Film-coated tablet; Oral

ABBV-599 Low Dose (Elsubrutinib 60 mg/upadacitinib 15 mg)

60 mg elsubrutinib capsule once a day by mouth for up to 24 weeks; 15 mg upadacitinib film-coated tablet once a day by mouth for up to 24 weeks

Group Type EXPERIMENTAL

Elsubrutinib

Intervention Type DRUG

Capsule; Oral

Upadacitinib

Intervention Type DRUG

Film-coated tablet; Oral

Elsubrutinib 60 mg/upadacitinib placebo

60 mg elsubrutinib capsule once a day by mouth for up to 24 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for up to 24 weeks

Group Type EXPERIMENTAL

Elsubrutinib

Intervention Type DRUG

Capsule; Oral

Placebo for upadacitinib

Intervention Type DRUG

Film-coated tablet; Oral

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Elsubrutinib

Capsule; Oral

Intervention Type DRUG

Placebo for elsubrutinib

Capsule; Oral

Intervention Type DRUG

Upadacitinib

Film-coated tablet; Oral

Intervention Type DRUG

Placebo for upadacitinib

Film-coated tablet; Oral

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ABBV-105 RINVOQ

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participant has clinical diagnosis of Systemic Lupus Erythematosus (SLE) at least 24 weeks prior to Screening, meeting at least 4 of the 11 revised Criteria for Classification of SLE according to the 1997 Update of the 1982 American College of Rheumatology (ACR) OR meeting at least 4 of the 2012 SLICC classification criteria, including at least 1 clinical criterion and 1 immunologic criterion.
* At Screening, must have at least one of the following:

* antinuclear antibody (ANA)+ (titer ≥ 1:80)
* anti-dsDNA+
* anti-Smith+
* SLEDAI-2K (SLE Disease Activity Index) ≥ 6 despite background therapy as reported and independently adjudicated (clinical score ≥ 4, excluding lupus headache and/or organic brain syndrome) at Screening:

* If 4 points of the required entry points are for arthritis, there must also be a minimum of 3 tender and 3 swollen joints.
* If participant has rash and Principal Investigator (PI) considers it to be attributable to SLE, participant must consent to skin photograph collection for adjudication.
* Score must be re-confirmed at the Baseline visit.
* Physician's Global Assessment (PhGA) ≥ 1 during screening period.
* Must be on background treatment, stable for 30 days prior to Baseline and throughout the study with antimalarial(s), prednisone (or prednisone equivalent) (≤ 20 mg), azathioprine (≤ 150 mg), mycophenolate (\<2 g), leflunomide (≤ 20 mg), cyclosporine, tacrolimus, and/or methotrexate (MTX) (≤ 20 mg).

* No combinations of the above with immunomodulators other than prednisone (or equivalents) and antimalarials.

Exclusion Criteria

\- Participant using intravenous (IV) or intramuscular (IM) corticosteroids greater than or equal to a 40 mg prednisone-equivalent bolus within 30 days of planned randomization.
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AbbVie

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

ABBVIE INC.

Role: STUDY_DIRECTOR

AbbVie

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Arizona Arthritis & Rheumatology Research, PLLC /ID# 214522

Mesa, Arizona, United States

Site Status

AZ Arthritis and Rheumotology Research, PLLC /ID# 211329

Phoenix, Arizona, United States

Site Status

AZ Arthritis and Rheumotology Research, PLLC /ID# 214267

Phoenix, Arizona, United States

Site Status

Arthritis and Rheumatism Associates /ID# 211411

Jonesboro, Arkansas, United States

Site Status

Wallace Rheumatic Studies Center, LLC /ID# 211600

Beverly Hills, California, United States

Site Status

Arthritis & Osteo Medical Ctr /ID# 228235

La Palma, California, United States

Site Status

Valerius Medical Group & Research Center /ID# 211599

Los Alamitos, California, United States

Site Status

East Bay Rheumatology Medical /ID# 211638

San Leandro, California, United States

Site Status

The Lundquist Institute at Harbor-UCLA Medical Center /ID# 213402

Torrance, California, United States

Site Status

Medvin Clinical Research /ID# 211996

Tujunga, California, United States

Site Status

Inland Rheum Clin Trials Inc. /ID# 213617

Upland, California, United States

Site Status

University of Colorado Hospital /ID# 211314

Aurora, Colorado, United States

Site Status

Yale University /ID# 212824

New Haven, Connecticut, United States

Site Status

Medstar Health Research Institute /ID# 213335

Washington D.C., District of Columbia, United States

Site Status

Arthritis & Rheumatic Disease Specialties /ID# 214052

Aventura, Florida, United States

Site Status

LeJenue Research Associates /ID# 212327

Miami, Florida, United States

Site Status

Ctr Arthritis & Rheumatic Dise /ID# 212326

Miami, Florida, United States

Site Status

Millennium Research /ID# 219099

Ormond Beach, Florida, United States

Site Status

IRIS Research and Development, LLC /ID# 213053

Plantation, Florida, United States

Site Status

West Broward Rheumatology Associates /ID# 211881

Tamarac, Florida, United States

Site Status

BayCare Medical Group, Inc. /ID# 218818

Tampa, Florida, United States

Site Status

Affinity Clinical Research /ID# 211496

Oak Brook, Illinois, United States

Site Status

Deerbrook Medical Associates /ID# 212251

Vernon Hills, Illinois, United States

Site Status

Qualmedica Research, LLC /ID# 214765

Evansville, Indiana, United States

Site Status

University of Iowa Hospitals and Clinics /ID# 215246

Iowa City, Iowa, United States

Site Status

The Center for Rheumatology and Bone Research /ID# 211610

Wheaton, Maryland, United States

Site Status

Beth Israel Deaconess Medical Center /ID# 212321

Boston, Massachusetts, United States

Site Status

Henry Ford Health System /ID# 211676

Detroit, Michigan, United States

Site Status

June DO, PC /ID# 211674

Lansing, Michigan, United States

Site Status

West County Rheumatology /ID# 225051

St Louis, Missouri, United States

Site Status

NYU Langone Ambulatory Care Brooklyn Heights /ID# 211548

Brooklyn, New York, United States

Site Status

NYU Langone Orthopedic Center /ID# 213620

New York, New York, United States

Site Status

Ohio State University - Wexner Medical Center /ID# 211636

Columbus, Ohio, United States

Site Status

STAT Research, Inc. /ID# 211404

Vandalia, Ohio, United States

Site Status

Premier Rheumatology of Oklahoma /ID# 213850

Tulsa, Oklahoma, United States

Site Status

Allegheny Health Network Research Institute /ID# 211607

Pittsburgh, Pennsylvania, United States

Site Status

Univ TN Health Sciences Ctr /ID# 212177

Memphis, Tennessee, United States

Site Status

Dr. Ramesh Gupta /ID# 213381

Memphis, Tennessee, United States

Site Status

Tekton Research, Inc. /ID# 211521

Austin, Texas, United States

Site Status

Tekton Research, Inc. /ID# 214182

Austin, Texas, United States

Site Status

Trinity Universal Research Associates - Carrollton /ID# 211527

Carrollton, Texas, United States

Site Status

Accurate Clinical Management /ID# 213571

Houston, Texas, United States

Site Status

West Texas Clinical Research /ID# 211529

Lubbock, Texas, United States

Site Status

SW Rheumatology Res. LLC /ID# 211520

Mesquite, Texas, United States

Site Status

Carilion Clinic /ID# 213500

Roanoke, Virginia, United States

Site Status

Virginia Mason Medical Center /ID# 211457

Seattle, Washington, United States

Site Status

Rheumatology and Pulmonary Clinic /ID# 211398

Beckley, West Virginia, United States

Site Status

Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich /ID# 221685

Ciudad Autonoma Buenos Aires, Buenos Aires, Argentina

Site Status

Hospital Interzonal General de Agudos General Jose de San Martin /ID# 211679

La Plata, Buenos Aires, Argentina

Site Status

CER Instituto Medico /ID# 222757

Quilmes, Buenos Aires, Argentina

Site Status

Aprillus Asistencia e Investigacion /ID# 211630

Ciudad Autonoma de Buenos Aire, Ciuadad Autonoma de Buenos Aires, Argentina

Site Status

Centro de Enfermedades del Hígado y Aparato Digestivo /ID# 211634

Rosario, Santa Fe Province, Argentina

Site Status

Instituto CAICI S.R.L /ID# 211633

Rosario, Santa Fe Province, Argentina

Site Status

Centro de Investigaciones Medicas Tucuman /ID# 212714

San Miguel de Tucumán, Tucumán Province, Argentina

Site Status

Investigaciones Clinicas Tucuman /ID# 211942

San Miguel de Tucumán, Tucumán Province, Argentina

Site Status

Hospital Cordoba /ID# 212200

Córdoba, , Argentina

Site Status

Emeritus Research Sydney /ID# 222983

Botany, New South Wales, Australia

Site Status

Royal North Shore Hospital /ID# 222982

St Leonards, New South Wales, Australia

Site Status

Royal Brisbane and Women's Hospital /ID# 212667

Herston, Queensland, Australia

Site Status

Rheumatology Research Unit Sunshine Coast /ID# 211902

Maroochydore, Queensland, Australia

Site Status

Griffith University /ID# 223543

Southport, Queensland, Australia

Site Status

The Queen Elizabeth Hospital /ID# 211901

Woodville South, South Australia, Australia

Site Status

Emeritus Research /ID# 211903

Camberwell, Victoria, Australia

Site Status

Monash Medical Centre /ID# 212313

Clayton, Victoria, Australia

Site Status

St Vincent's Hospital Melbourne /ID# 212311

Fitzroy Melbourne, Victoria, Australia

Site Status

UMHAT Kaspela EOOD /ID# 223141

Plovdiv, , Bulgaria

Site Status

UMHAT Sveti Ivan Rilski /ID# 223139

Sofia, , Bulgaria

Site Status

UMHAT Sveti Ivan Rilski /ID# 223140

Sofia, , Bulgaria

Site Status

Hamilton Health Sciences - McMaster University Medical Centre /ID# 212662

Hamilton, Ontario, Canada

Site Status

St. Josephs Health Care Centre /ID# 212331

London, Ontario, Canada

Site Status

Toronto Western Hospital /ID# 213336

Toronto, Ontario, Canada

Site Status

Diex Recherche Sherbrooke Inc. /ID# 217734

Sherbrooke, Quebec, Canada

Site Status

Anhui Provincial Hospital /ID# 211812

Hefei, Anhui, China

Site Status

Peking Union Medical College Hospital /ID# 211614

Beijing, Beijing Municipality, China

Site Status

Guangdong Provincial People's Hospital /ID# 211811

Guangzhou, Guangdong, China

Site Status

Xiangya Hospital Central South University /ID# 212919

Changsha, Hunan, China

Site Status

Jiangsu Province Hospital /ID# 211818

Nanjing, Jiangsu, China

Site Status

Huashan Hospital, Fudan University /ID# 213976

Shanghai, Shanghai Municipality, China

Site Status

Shanghai Changhai Hospital /ID# 211819

Shanghai, Shanghai Municipality, China

Site Status

People's Hospital of Xinjiang /ID# 211821

Ürümqi, , China

Site Status

Centro Integral de Reumatologia del Caribe Circaribe SAS /ID# 211894

Barranquilla, Atlántico, Colombia

Site Status

Centro de Investigacion en Reumatologia y Especialidades Medicas- CIREEM SAS /ID# 211895

Bogota, Cundinamarca, Colombia

Site Status

Preventive Care Sas /Id# 211896

Chía, Cundinamarca, Colombia

Site Status

Healthy Medical Center SAS /ID# 211899

Zipaquirá, Cundinamarca, Colombia

Site Status

Clinica Universitaria Bolivari /ID# 211897

Medellín, , Colombia

Site Status

CHRU Lille - Hopital Claude Huriez /ID# 211829

Lille, Hauts-de-France, France

Site Status

CHU Bordeaux - Hopital Pellegrin /ID# 211832

Bordeaux, , France

Site Status

AP-HP - Hôpital Bicêtre /ID# 211968

Le Kremlin-Bicêtre, , France

Site Status

Hopital Pitie Salpetriere /ID# 211831

Paris, , France

Site Status

CHU Strasbourg - Hopital Civil /ID# 211981

Strasbourg, , France

Site Status

Universitaetsklinikum Duesseldorf /ID# 212408

Düsseldorf, North Rhine-Westphalia, Germany

Site Status

Universitaetsklinikum Schleswig-Holstein Campus Kiel /ID# 212674

Kiel, Schleswig-Holstein, Germany

Site Status

Charite Universitaetsmedizin Berlin - Campus Mitte /ID# 211988

Berlin, , Germany

Site Status

Universitaetsklinikum Carl Gustav Carus an der TU Dresden /ID# 212770

Dresden, , Germany

Site Status

Debreceni Egyetem Klinikai Kozpont /ID# 212042

Debrecen, Hajdú-Bihar, Hungary

Site Status

Vital Medical Center Orvosi es Fogaszati Kozpont /ID# 212796

Veszprém, Veszprém megye, Hungary

Site Status

Orszagos Reumatologiai es Fizioterapias Intezet /ID# 211827

Budapest, , Hungary

Site Status

Bekes Megyei Kozponti Korhaz Pandy Kalman Tagkorhaz /ID# 216971

Gyula, , Hungary

Site Status

Azienda Ospedaliero-Universitaria di Ferrara-Arcispedale Sant Anna /ID# 211861

Cona, Ferrara, Italy

Site Status

Azienda Ospedaliero-Universitaria Policlinico Umberto I /ID# 212195

Rome, Lazio, Italy

Site Status

ASST Gaetano Pini/Presidio Ospedaliero Pini /ID# 215063

Milan, , Italy

Site Status

Azienda Ospedaliera Universitaria Friuli Centrale/Presidio Ospedaliero Universit /ID# 211858

Udine, , Italy

Site Status

Chukyo Hospital /ID# 222625

Nagoya, Aichi-ken, Japan

Site Status

NHO Nagoya Medical Center /ID# 213974

Nagoya, Aichi-ken, Japan

Site Status

Hamanomachi Hospital /ID# 213696

Fukuoka, Fukuoka, Japan

Site Status

Hospital of the University of Occupational and Environmental Health, Japan /ID# 217548

Kitakyushu-shi, Fukuoka, Japan

Site Status

Fukushima Medical University Hospital /ID# 213913

Fukushima, Fukushima, Japan

Site Status

Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital /ID# 213694

Hiroshima, Hiroshima, Japan

Site Status

National Hospital Organization Asahikawa Medical Center /ID# 213846

Asahikawa-shi, Hokkaido, Japan

Site Status

Tomakomai City Hospital /ID# 214234

Tomakomai-shi, Hokkaido, Japan

Site Status

Kita-harima Medical Center /ID# 215474

Ono-shi, Hyōgo, Japan

Site Status

EIRAKU Internal Medicine Clinic /ID# 215419

Kagoshima, Kagoshima-ken, Japan

Site Status

Yokohama Rosai Hospital /ID# 213690

Yokohama, Kanagawa, Japan

Site Status

Kumamoto Shinto General Hospital /ID# 215347

Kumamoto, Kumamoto, Japan

Site Status

Tohoku University Hospital /ID# 213693

Sendai, Miyagi, Japan

Site Status

Shinshu University Hospital /ID# 213853

Matsumoto-shi, Nagano, Japan

Site Status

Nagano Red Cross Hospital /ID# 214572

Nagano, Nagano, Japan

Site Status

Saitama Medical Center /ID# 213687

Kawagoe-shi, Saitama, Japan

Site Status

Keio University Hospital /ID# 216347

Shinjuku-ku, Tokyo, Japan

Site Status

Morales Vargas Centro de Investigacion S.C. /ID# 212946

León, Guanajuato, Mexico

Site Status

Centro Integral en Reumatologia S.A de C.V /ID# 211876

Guadalajara, Jalisco, Mexico

Site Status

Centro de Estudios de Investigación Básica y Clínica, S.C. /ID# 212532

Guadalajara, Jalisco, Mexico

Site Status

RM Pharma Specialists S.A de C.V. /ID# 211879

Mexico City, Mexico City, Mexico

Site Status

CINTRE, Centro de Investigación y Tratamiento Reumatológico SC /ID# 211875

Mexico City, Mexico City, Mexico

Site Status

Centro de Alta Especialidad en Reumatología e Investigación del Potosí, SC /ID# 212737

San Luis Potosí City, San Luis Potosí, Mexico

Site Status

Medical Care & Research SA de CV /ID# 212682

Mérida, Yucatán, Mexico

Site Status

Vrije Universiteit Medisch Centrum /ID# 214424

Amsterdam, , Netherlands

Site Status

Leids Universitair Medisch Centrum /ID# 214413

Leiden, , Netherlands

Site Status

Universitair Medisch Centrum Utrecht /ID# 214415

Utrecht, , Netherlands

Site Status

Middlemore Clinical Trials /ID# 213504

Papatoetoe, Auckland, New Zealand

Site Status

North Shore Hospital /ID# 213506

Takapuna, Auckland, New Zealand

Site Status

Waikato Hospital /ID# 213505

Hamilton, Waikato Region, New Zealand

Site Status

Ortopedyczno-Rehabilitacyjny Szpital Kliniczny im. Wiktora Degi /ID# 212483

Poznan, Greater Poland Voivodeship, Poland

Site Status

Centrum Nowoczesnych Terapii Dobry Lekarz Sp. z o.o. /ID# 212146

Krakow, Lesser Poland Voivodeship, Poland

Site Status

WroMedica I. Bielicka, A. Strzalkowska s.c. /ID# 212482

Wroclaw, Lower Silesian Voivodeship, Poland

Site Status

Centrum Medyczne Pratia Warszawa /ID# 218176

Warsaw, Masovian Voivodeship, Poland

Site Status

GCM Medical Group PSC /ID# 211251

San Juan, , Puerto Rico

Site Status

Mindful Medical Research /ID# 213384

San Juan, , Puerto Rico

Site Status

Ajou University Hospital /ID# 211692

Suwon, Gyeonggido, South Korea

Site Status

KonKuk University Medical Center /ID# 213410

Seoul, Seoul Teugbyeolsi, South Korea

Site Status

Chonnam National University Hospital /ID# 211695

Gwangju, , South Korea

Site Status

Inha University Hospital /ID# 211691

Incheon, , South Korea

Site Status

Seoul National University Hospital /ID# 211740

Seoul, , South Korea

Site Status

HUA - Txagorritxu /ID# 212520

Vitoria-Gasteiz, Alava, Spain

Site Status

Consorci Corporacio Sanitaria Parc Tauli Sabadell /ID# 212145

Sabadell, Barcelona, Spain

Site Status

Hospital Universitario Basurto /ID# 212722

Bilbao, Vizcaya, Spain

Site Status

Hospital Universitario de Galdakao /ID# 212803

Galdakao, Vizcaya, Spain

Site Status

Hospital Universitario A Coruna - CHUAC /ID# 211719

A Coruña, , Spain

Site Status

Hospital Universitario 12 de Octubre /ID# 211757

Madrid, , Spain

Site Status

Hospital Universitario Virgen de Valme /ID# 212721

Seville, , Spain

Site Status

Hospital Universitario y Politecnico La Fe /ID# 211720

Valencia, , Spain

Site Status

China Medical University Hospital /ID# 212179

Taichung, , Taiwan

Site Status

Taichung Veterans General Hospital /ID# 211957

Taichung, , Taiwan

Site Status

National Taiwan University Hospital /ID# 211752

Taipei, , Taiwan

Site Status

Taipei Medical University Hospital /ID# 221600

Taipei, , Taiwan

Site Status

Taipei Veterans General Hosp /ID# 212216

Taipei, , Taiwan

Site Status

Linkou Chang Gung Memorial Hospital /ID# 211751

Taoyuan, , Taiwan

Site Status

Guys and St Thomas NHS Foundation Trust /ID# 211931

London, London, City of, United Kingdom

Site Status

Cambridge University Hospitals NHS Foundation Trust /ID# 213189

Cambridge, , United Kingdom

Site Status

Manchester University NHS Foundation Trust /ID# 211838

Manchester, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina Australia Bulgaria Canada China Colombia France Germany Hungary Italy Japan Mexico Netherlands New Zealand Poland Puerto Rico South Korea Spain Taiwan United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Hannon CW, McCourt C, Lima HC, Chen S, Bennett C. Interventions for cutaneous disease in systemic lupus erythematosus. Cochrane Database Syst Rev. 2021 Mar 9;3(3):CD007478. doi: 10.1002/14651858.CD007478.pub2.

Reference Type DERIVED
PMID: 33687069 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Related Links

Access external resources that provide additional context or updates about the study.

https://www.rxabbvie.com/

This clinical study may be evaluating a usage that is not currently FDA approved. Please see US Prescribing Information for approved uses.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2019-000638-20

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

M19-130

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Synergetic B-cell Immodulation in SLE
NCT02284984 COMPLETED PHASE2
Belimumab Assessment of Safety in SLE
NCT01705977 COMPLETED PHASE4